Skip to content
Disclosery

Ally Bridge Group (NY) LLC

Follow

13F filer, CIK 1822947, NEW YORK, NY

Ally Bridge Group (NY) LLC reported $164,215,533 across 24 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14. Its ten largest share positions make up 79.16% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-25-283054

Period
2025-09-30
Reported value
$164M
Holdings
24
Top 10 weight
79.16%
New
14
Sold out
14

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MDGLnew+32,662$15M
ATAIBECKLEY INCnew+2,287,005$12.1M
ASNDnew+51,080$10.2M
SLNOadded+123,664$8.36M
TSHAnew+1,898,112$6.21M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
VERONA PHARMA PLCexited-160,701-$15.2M
LENZreduced-167,959-$7.82M
MERUS N Vexited-140,208-$7.37M
ULTRAGENYX PHARMACEUTICAL INexited-1,600-$5.82M
ELVNexited-281,394-$5.64M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001193125-25-283054, largest first. % of portfolio is the value over $119,439,102, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 87,629 shares; 2025Q1: 120,449 shares; 2025Q2: 178,819 shares; 2025Q3: 302,483 shares 302,483$20.4M17.12%+123,664Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 32,662 shares 32,662$15M12.54%newTimeline
ATAIBECKLEY INCATAIBECKLEY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,287,005 shares 2,287,005$12.1M10.13%new
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 51,080 shares 51,080$10.2M8.5%newTimeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 343,322 shares; 2025Q3: 175,363 shares 175,363$8.17M6.84%-167,959Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,898,112 shares 1,898,112$6.21M5.2%newTimeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 437,391 shares 437,391$5.94M4.98%newTimeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,485,000 shares; 2025Q3: 1,026,382 shares 1,026,382$5.88M4.92%-458,618Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 915,000 shares 915,000$5.4M4.52%newTimeline
MNPRMONOPAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 34,537 shares; 2025Q3: 64,455 shares 64,455$5.26M4.41%+29,918Timeline
ARQTARCUTIS BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 233,220 shares 233,220$4.4M3.68%newTimeline
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 788,508 shares; 2024Q4: 330,275 shares; 2025Q1: 390,143 shares; 2025Q2: 726,172 shares; 2025Q3: 361,444 shares 361,444$4.26M3.57%-364,728
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 321,898 shares; 2024Q4: 173,144 shares; 2025Q1: 127,932 shares; 2025Q2: 121,182 shares; 2025Q3: 70,778 shares 70,778$4.21M3.52%-50,404Timeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 724,000 shares; 2025Q3: 549,182 shares 549,182$3.39M2.84%-174,818Timeline
PROMIS NEUROSCIENCES INCPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,592,605 shares; 2024Q4: 1,592,605 shares; 2025Q1: 1,484,699 shares; 2025Q2: 1,334,428 shares; 2025Q3: 6,233,497 shares 6,233,497$2.65M2.22%+4,899,069
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 178,100 shares 178,100$2.26M1.9%newTimeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 132,222 shares; 2025Q2: 163,683 shares; 2025Q3: 138,595 shares 138,595$2.17M1.82%-25,088Timeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 817,939 shares; 2025Q1: 817,939 shares; 2025Q2: 817,939 shares; 2025Q3: 817,939 shares 817,939$1.55M1.3%0Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
SLNOSOLENO THERAPEUTICS INC COMcall250,000$16.9Mnew
REPLREPLIMUNE GROUP INC COMMON STOCKcall3,600,000$15.1Mnew
CMPSCOMPASS PATHWAYS PLC SPONSORED ADScall1,145,700$6.56Mnew
PRAXPRAXIS PRECISION MEDICINES I COM NEWcall100,000$5.3Mnew
MLTXMOONLAKE IMMUNOTHERAPEUTICS Stockcall69,000$495Knew
ATYRATYR PHARMA INC COM NEWcall600,000$433Knew

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VERONA PHARMA PLCVERONA PHARMA PLC160,701$15.2Mshares
MERUS N VMERUS N V140,208$7.37Mshares
ULTRAGENYX PHARMACEUTICAL INULTRAGENYX PHARMACEUTICAL IN1,600$5.82Mshares
ELVNENLIVEN THERAPEUTICS INC281,394$5.64Mshares
ORICORIC PHARMACEUTICALS INC485,629$4.93Mshares
REPLREPLIMUNE GROUP INC528,491$4.91Mshares
INSMINSMED INC47,710$4.8Mshares
GERNGERON CORP3,251,475$4.58Mshares
CNTACENTESSA PHARMACEUTICALS PLC293,986$3.86Mshares
RNAMAVIDITY BIOSCIENCES INC132,744$3.77Mshares
LXEOLEXEO THERAPEUTICS INC867,302$3.49Mshares
PRAXPRAXIS PRECISION MEDICINES I80,880$3.4Mshares
KRROKORRO BIO INC154,223$1.93Mshares
ATYRATYR PHARMA INC287,720$1.46Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-25-283054 base2025-11-14acceptance time not in the bulk data set